Disrupting the flow: How UFM1 mutations compromise brain development
In a nutshell
UFMylation is a process where the ubiquitin-like protein UFM1 is attached to other proteins as post-translational modification, acting like a “tag”.
The UFM1 system is crucial for the ribosome and the endoplasmic reticulum (ER) — the cell's protein-producing factories — to function correctly under stress.
New research shows that encephalopathy-linked mutations in the UFM1 system impede the "tagging" process, causing protein production to stall in neurons.
Failed UFMylation leads to stunted brain development and impaired neuronal function, which may explain the symptoms observed in affected children.
Therapeutic options for restoring protein production are explored in order to treat symptoms of UFM1-associated diseases.
UFM1 mutations impede neuronal development and function
Imagine a high-speed automated factory (the ribosome) producing complex machinery (proteins). In order for the factory to run smoothly, it needs a quality inspector to mark components that are stuck or misaligned. The UFM1 system is one such inspector. It attaches a "tag" (the UFM1 protein) to the factory equipment to signal that a blockage needs to be cleared. Without this tag, the assembly line jams.
In the brain, where neurons must produce a wide variety of proteins to grow and communicate, these "jams" can be fatal. If the quality control system fails, the neuron cannot complete its development, leading to neurodevelopmental defects.
A research team led by Marilyn Tirard and Nils Brose of the Department of Molecular Neurobiology at the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT) in Göttingen (Germany), together with the institute’s Neuroproteomics Group headed by Olaf Jahn, investigated how specific genetic variants of UFM1 found in patients with severe brain development issues alter this process. This study was done in collaboration with Mateusz Ambrozkiewicz from the Charité - Universitätsmedizin Berlin, and Yogesh Kulathu from the University of Dundee (United Kingdom).
Using a combination of advanced biochemistry and neuronal models, the scientists found that these UFM1 disease-linked variants are significantly less efficient at attaching UFM1 to its targets. Advanced image analysis revealed that, as a result, fewer proteins are produced and the ER becomes stressed.
The study demonstrates that this is not just a minor slowdown — it is a fundamental "jam" at the molecular level. Neurons carrying these variants show fewer dendrites and a reduced ability to form the synapses necessary for brain function. This provides a link between failure in the UFM1 system in tagging proteins and the symptoms of developmental delay seen in patients.
A new roadmap for rare diseases
The discovery highlights the UFM1 system as a critical "proteostasis" regulatory center responsible for maintaining the proper balance in protein production, as required for a fully functional brain. By pinpointing exactly where the tagging process fails, the researchers have progressed from describing a disease to understanding its fundamental molecular mechanics. This work not only explains the mechanisms of UFM1-related encephalopathy but also adds to our broader understanding of how protein production "checkpoints" are vital for human neurodevelopment.
In the future, these insights could pave the way for targeted therapies aimed at restoring the balance of protein production in affected cells. Indeed, the scientists observed positive effects of a clinically used drug under a defective UFM1 system, providing the first encouraging steps toward this direction.
This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; SFB1286-A01/A03/A09, and projects 515247130 and 536563141), and the Fritz Thyssen Foundation (10.23.2.003MN).
